ArticleSkeletal muscle2021
Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study.
Article in Skeletal muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04734496 (Evaluation of Mechanisms of Sarcopenia in Chronic Inflammatory Disease), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Mechanisms of Sarcopenia in Chronic Inflammatory Disease (Chronic Liver Disease, Inflammatory Bowel Disease and Inflammatory Arthritis) Pre and Post Standard of Care Intervention; an Observational Study
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Observational
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- The impact of sarcopenia on the progression of chronic non-bacterial osteomyelitis.Insights into imaging · 2025Article
- Sarcopenia as a Prognostic Factor and Multimodal Interventions in Breast Cancer.International journal of general medicine · 2024Article
- Impaired lower limb muscle mass, quality and function in end stage liver disease: A cross-sectional study.Experimental physiology · 2023Article
- Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future.Current treatment options in gastroenterology · 2022Article
- Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia.Proteomes · 2022Review
- Study of Comparison of Handgrip Dynamometer and Transverse Psoas Muscle Thickness as a Predictor of Short-term Morbidity and Mortality in Patients of Chronic Liver Disease.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSeveral chronic inflammatory diseases co-exist with and accelerate sarcopenia (reduction in muscle strength, function and mass) and negatively impact on both morbidity and mortality. There is currently limited research on the extent of sarcopenia in such conditions, how to accurately assess it and whether there are generic or disease-specific mechanisms driving sarcopenia. Therefore, this study aims to identify potential mechanisms driving sarcopenia within chronic inflammatory disease via a multi-modal approach; in an attempt to help define potential interventions for future use.
methodsThis prospective cohort study will consist of a multi-modal assessment of sarcopenia and its underlying mechanisms. Recruitment will target three chronic inflammatory diseases: chronic liver disease (CLD) (n=50), with a subset of NAFLD (n=20), inflammatory bowel disease (IBD) (n=50) and rheumatoid arthritis (RA) (n=50) both before and after therapeutic intervention. In addition, 20 age and sex matched healthy individuals will be recruited for comparison. Participants will undergo 4 assessment visits at weeks 0, 2, 12 and 24. Visits will consist of the following assessments: blood tests, anthropometrics, functional assessment, quadriceps muscle imaging, actigraphy, quality of life questionnaires, food diary collection and muscle biopsy of the vastus lateralis (at weeks 2 and 24 only). In addition, stool and urine samples will be collected for future microbiome and metabolomics analysis. DISCUSSION: This is the first study to use a multi-modal assessment model to phenotype sarcopenia in these chronic inflammatory diseases. We hope to identify generic as well as disease-specific mechanisms driving sarcopenia. We appreciate that these cohorts do require separate standards of care treatments which limit comparison between groups. ETHICS AND DISSEMINATION: The study is approved by the Health Research Authority - West Midlands Solihull Research Ethics Service Committee Authority (REC reference: 18/WM/0167). Recruitment commenced in January 2019 and will continue until July 2021. The study was halted in March 2020 and again in January 2021 with the COVID-19 pandemic. The findings will be disseminated through peer-reviewed publications and conference presentations. All data will be stored on a secure server.
trial registrationClinicalTrials.gov Identifier: NCT04734496.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.